-
Something wrong with this record ?
Multiplex biomarker approach to cardiovascular diseases
M. Adamcova, F. Šimko,
Language English Country United States
Document type Journal Article, Review
NLK
Free Medical Journals
from 1980
PubMed Central
from 2009 to 1 year ago
Europe PubMed Central
from 2009 to 1 year ago
ProQuest Central
from 2005-01-01 to 1 year ago
Open Access Digital Library
from 2009-01-01
Health & Medicine (ProQuest)
from 2005-01-01 to 1 year ago
PubMed
29645001
DOI
10.1038/aps.2018.29
Knihovny.cz E-resources
- MeSH
- Biomarkers analysis MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Cardiovascular Diseases diagnosis drug therapy MeSH
- Humans MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Personalized medicine is partly based on biomarker-guided diagnostics, therapy and prognosis, which is becoming an unavoidable concept in modern cardiology. However, the clinical significance of single biomarker studies is rather limited. A promising novel approach involves combining multiple markers into a multiplex panel, which could refine the management of a particular patient with cardiovascular pathology. Two principally different assay formats have been developed to facilitate simultaneous quantification of multiple antigens: planar array assays and microbead assays. These approaches may help to better evaluate the complexity and dynamic nature of pathologic processes and offer substantial cost and sample savings compared with traditional enzyme-linked immunosorbent assay (ELISA) measurements. However, a multiplex multimarker approach cannot become a generally disseminated method until analytical problems are solved and further studies confirming improved clinical outcomes are accomplished. These drawbacks underlie the fact that a limited number of systematic studies are available regarding the use of a multiplex biomarker approach in cardiovascular medicine to date. Our perspective underscores the significant potential of the use of the multiplex approach in a wider conceptual framework under the close cooperation of clinical and experimental cardiologists, pathophysiologists and biochemists so that the personalized approach based on standardized multimarker testing may improve the management of various cardiovascular pathologies and become a ubiquitous partner of population-derived evidence-based medicine.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000808
- 003
- CZ-PrNML
- 005
- 20190111144817.0
- 007
- ta
- 008
- 190107s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/aps.2018.29 $2 doi
- 035 __
- $a (PubMed)29645001
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Adamcova, Michaela $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic. adamcova@lfhk.cuni.cz.
- 245 10
- $a Multiplex biomarker approach to cardiovascular diseases / $c M. Adamcova, F. Šimko,
- 520 9_
- $a Personalized medicine is partly based on biomarker-guided diagnostics, therapy and prognosis, which is becoming an unavoidable concept in modern cardiology. However, the clinical significance of single biomarker studies is rather limited. A promising novel approach involves combining multiple markers into a multiplex panel, which could refine the management of a particular patient with cardiovascular pathology. Two principally different assay formats have been developed to facilitate simultaneous quantification of multiple antigens: planar array assays and microbead assays. These approaches may help to better evaluate the complexity and dynamic nature of pathologic processes and offer substantial cost and sample savings compared with traditional enzyme-linked immunosorbent assay (ELISA) measurements. However, a multiplex multimarker approach cannot become a generally disseminated method until analytical problems are solved and further studies confirming improved clinical outcomes are accomplished. These drawbacks underlie the fact that a limited number of systematic studies are available regarding the use of a multiplex biomarker approach in cardiovascular medicine to date. Our perspective underscores the significant potential of the use of the multiplex approach in a wider conceptual framework under the close cooperation of clinical and experimental cardiologists, pathophysiologists and biochemists so that the personalized approach based on standardized multimarker testing may improve the management of various cardiovascular pathologies and become a ubiquitous partner of population-derived evidence-based medicine.
- 650 _2
- $a biologické markery $x analýza $7 D015415
- 650 _2
- $a kardiovaskulární nemoci $x diagnóza $x farmakoterapie $7 D002318
- 650 _2
- $a ELISA $7 D004797
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Šimko, Fedor $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic. Third Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic. Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovak Republic.
- 773 0_
- $w MED00193644 $t Acta pharmacologica Sinica $x 1745-7254 $g Roč. 39, č. 7 (2018), s. 1068-1072
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29645001 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190111145022 $b ABA008
- 999 __
- $a ok $b bmc $g 1363928 $s 1038931
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 39 $c 7 $d 1068-1072 $e 20180412 $i 1745-7254 $m Acta pharmacologica Sinica $n Acta Pharmacol Sin $x MED00193644
- LZP __
- $a Pubmed-20190107